Femme et Homme
- | Pays :
- Sweden
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
Critère d'inclusion
- Hematologic Neoplasms ,Prostatic Neoplasms